Clare Hird
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 5%
- Long-Term Effects of COVID-19
Papers in
-
- COVID-19 Clinical Research Studies 6
- SARS-CoV-2 and COVID-19 Research 3
-
- Nosocomial Infections in ICU 2
- Thermal Regulation in Medicine 1
- Co-authors
- Mike Parker (1 shared paper)
- Journals
- The Lancet (6 papers)JAMA (5 papers)EClinicalMedicine (1 paper)Intensive Care Medicine (1 paper)Cell (1 paper)
- Partner nations
- United KingdomAustraliaIndonesia
In The Last Decade
Clare Hird
17 papers receiving 2.3k citations
Clare Hird's Hit Papers
Peers
Comparison fields: 5 of 109
- Infectious Diseases 1.3k
- Neurology 489
- Applied Microbiology and Biotechnology 52
- Internal Medicine 84
- Critical Care and Intensive Care Medicine 102
Countries citing papers authored by Clare Hird
This map shows the geographic impact of Clare Hird's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clare Hird with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clare Hird more than expected).
Fields of papers citing papers by Clare Hird
This network shows the impact of papers produced by Clare Hird. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clare Hird. The network helps show where Clare Hird may publish in the future.
Co-authors
The 1 scholars most cited alongside Clare Hird, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | A blood atlas of COVID-19 defines hallmarks of disease severity and specificity Hit paper breakdown → | 2022 | 209 |
| 7 | 2021 | 163 | |
| 8 | 2022 | 104 | |
| 9 | 2022 | 99 | |
| 10 | 2023 | 83 | |
| 11 | 2021 | 70 | |
| 12 | 2023 | 45 | |
| 13 | 2023 | 34 | |
| 14 | 2022 | 29 | |
| 15 | 2024 | 6 | |
| 16 | 2025 | 2 | |
| 17 | 2020 | 1 | |
| 18 | 2025 | 0 |
About Clare Hird
Clare Hird is a scholar working on Infectious Diseases, Critical Care and Intensive Care Medicine, Neurology, Pulmonary and Respiratory Medicine and Epidemiology, having authored 18 papers that have together received 2.4k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Sepsis Diagnosis and Treatment (2 papers), Nosocomial Infections in ICU (2 papers), Long-Term Effects of COVID-19 (2 papers), Respiratory Support and Mechanisms (2 papers), Thermal Regulation in Medicine (1 paper) and Vitamin C and Antioxidants Research (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Neurology (489 citations), Applied Microbiology and Biotechnology (52 citations), Internal Medicine (84 citations) and Critical Care and Intensive Care Medicine (102 citations). Clare Hird has collaborated with scholars based in United Kingdom, Australia and Indonesia. Frequent co-authors include Mike Parker. Their work appears in journals such as The Lancet, JAMA, EClinicalMedicine, Intensive Care Medicine and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.